What AI Changes Will We See In Big Pharma This Year?
Shannon Flynn is a freelance blogger who covers education technologies, cybersecurity and IoT topics. You can follow Shannon on Muck Rack or Medium to read more of her articles.
Artificial intelligence (AI) has had major impacts in the health care industry, affecting providers and patients alike. However, it also aids the pharmaceutical sector in finding and creating the drugs that support health care through the treatment and management of diseases. Here’s a closer look at some positive changes AI could bring this year.
1. More Applications of AI for Drug Discovery
Uncovering effective drugs can be a time-consuming process. However, AI could make it faster and more fruitful.
A recent partnership between Roche, its U.S. subsidiary Genentech and clinical-stage biotech company Recursion will involve using AI to find new drug targets and accelerate this phase of development. The arrangement could lead to up to 40 programs for neurology and cancer drugs over the next decade.
However, experts warn that applying AI to drug discovery could also have a dark side. One pharmaceutical company previously used AI to find beneficial therapeutics. However, it also relied on the technology to uncover new toxic nerve agents to use as bioweapons.
In less than six hours, the algorithms had found 40,000 molecules that fit the researchers’ desired parameters. They warned that their experiment should be a wake-up call. Depending on AI to find new drugs is promising, but some people could misuse the method’s potential.